NRC FORM 591M PART 1
(10-2003)
10 CFR 2.201

U.S. NUCLEAR REGULATORY COMMISSION

SAFETY INSPECTION REPORT AND COMPLIANCE INSPECTION

1. LICENSEE/LOCATION INSPECTED:	2. NRC/REGIONAL OFFICE
Kansas City Cancer Centers - South Kansas City, MO REPORT 2008-001	**U.S. Nuclear Regulatory Commission** **Region III** **2443 Warrenville Road** **Suite 210** **Lisle, Illinois 60532-4351**

3. DOCKET NUMBER(S)	4. LICENSEE NUMBER(S)	5. DATE(S) OF INSPECTION
030-36583	24-32517-01	April 29 - May 1, 2008

LICENSEE:

The inspection was an examination of the activities conducted under your license as they relate to radiation safety and to compliance with the Nuclear Regulatory Commission (NRC) rules and regulations and the conditions of your license. The inspection consisted of selective examinations of procedures and representative records, interviews with personnel, and observations by the inspector. The inspection findings are as follows:

☑ 1. Based on the inspection findings, no violations were identified.

☐ 2. Previous violation(s) closed.

☐ 3. The violation(s), specifically described to you by the inspector as non-cited violations, are not being cited because they were self-identified, non-repetitive, and corrective action was or is being taken, and the remaining criteria in the NRC Enforcement Policy, NUREG-1600, to exercise discretion, were satisfied.

_____ Non-Cited Violation(s) was/were discussed involving the following requirement(s) and Corrective Action(s):

☐ 4. During this inspection certain of your activities, as described below and/or attached, were in violation of NRC requirements and are being cited. This form is a NOTICE OF VIOLATION, which may be subject to posting in accordance with 10 CFR 19.11.

(Violations and Corrective Actions)

Licensee's Statement of Corrective Actions for Item 4, above.

I hereby state that, within 30 days, the actions described by me to the inspector will be taken to correct the violations identified. This statement of corrective actions is made in accordance with the requirements of 10 CFR 2.201 (corrective steps already taken, corrective steps which will be taken, date when full compliance will be achieved). I understand that no further written response to NRC will be required, unless specifically requested.

Title	Printed Name	Signature	Date
LICENSEE'S REPRESENTATIVE			
NRC INSPECTOR	Deborah A. Piskura	[signature]	5/1/2008

NRC FORM 591M PART 3
(10-2003) 10 CFR 2.201

Docket File Information

U.S. NUCLEAR REGULATORY COMMISSION

SAFETY INSPECTION REPORT AND COMPLIANCE INSPECTION

1. LICENSEE	2. NRC/REGIONAL OFFICE
Kansas City Cancer Centers-South REPORT NUMBER(S) 2008-001	**Region III** **2443 Warrenville Road, Suite 210** **Lisle, IL 60532**

3. DOCKET NUMBER(S)	4. LICENSE NUMBER(S)	5. DATE(S) OF INSPECTION
030-36583	24-32517-01	April 29 and May 1, 2008

6. INSPECTION PROCEDURES USED	7. INSPECTION FOCUS AREAS
87130, 87131, 87132	03.01 – 03.08

SUPPLEMENTAL INSPECTION INFORMATION

1. PROGRAM CODE(S)	2. PRIORITY	3. LICENSEE CONTACT	4. TELEPHONE NUMBER
02230	2	Brian Wichman, M.S.	913-234-0502

[X] Main Office Inspection — Next Inspection Date: May 2010

[X] Field Office — HDR suite, 8700 North Green Hills Road, Kansas City, MO

[ ] Temporary Job Site Inspection

PROGRAM SCOPE

This licensee was a private multi-specialty out-patient cancer care clinic. Licensed activities were authorized at three facilities located in the Kansas City metropolitan area. The licensee was authorized to use materials specified in Sections 35.300, and Ir-192 in an HDR unit. The licensee acquired its HDR unit in September 2007.

Typically, in a year the licensee administered 25 iodine-131 thyroid carcinoma treatments. The licensee obtained its I-131 in capsule form only. The department also administered 4-5 Sm-153 dosages for treatment of metastatic bone disease, and 3-4 Y-90 Zevalin treatments annually.

The radiation therapy department was staffed with 4 medical physicists, 8 dosimetrists, and 8 physicians (authorized users) and 4 therapy technologists. The licensee administered approximately 35 patient treatment series to date using its HDR unit; these treatments were for bronchial, breast, and gynecological cancers. All HDR patient treatments were administered by the attending radiation oncologist and the medical physicist (therapy technologists operated the controls to the HDR unit). Source exchange, maintenance, and repairs on the HDR unit were performed by the manufacturer.

This inspection consisted of interviews with selected licensee personnel, a review of selected records, tours of the nuclear medicine and radiation oncology departments, and independent measurements. The inspector observed one HDR brachytherapy treatment. The inspector reviewed the written directive for the procedure; observed the licensee performing daily QA checks and treatment planning; and observed the patient treatment and patient surveys at the conclusion of the treatment. The inspector also interviewed the physician authorized user and nurse who attended the patient.